Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Non-Current Assets (2016 - 2025)

Anaptysbio's Non-Current Assets history spans 10 years, with the latest figure at $14.1 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 72.78% year-over-year to $14.1 million; the TTM value through Dec 2025 reached $138.9 million, down 26.96%, while the annual FY2025 figure was $14.1 million, 72.78% down from the prior year.
  • Non-Current Assets reached $14.1 million in Q4 2025 per ANAB's latest filing, down from $22.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $168.1 million in Q3 2022 to a low of $9.3 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $69.3 million, with a median of $55.4 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: plummeted 82.54% in 2021, then skyrocketed 1114.17% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $89.2 million in 2021, then skyrocketed by 82.95% to $163.2 million in 2022, then crashed by 72.08% to $45.6 million in 2023, then grew by 14.06% to $52.0 million in 2024, then tumbled by 72.78% to $14.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Non-Current Assets are $14.1 million (Q4 2025), $22.4 million (Q3 2025), and $43.3 million (Q2 2025).